Luo Chun-Ying, Su Wei-Chao, Jiang Hai-Feng, Luo Ling-Tao, Shen Dong-Yan, Su Guo-Qiang
Medical College, Guangxi University, Nanning, 530004, Guangxi Province, People's Republic of China.
Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi Province, People's Republic of China.
Cancer Cell Int. 2023 Dec 19;23(1):333. doi: 10.1186/s12935-023-03126-y.
DPY30 belongs to the core subunit of components of the histone lysine methyltransferase complex, which is implicated in tumorigenesis, cell senescence, and other biological events. However, its contribution to colorectal carcinoma (CRC) progression and metastasis has yet to be elucidated. Therefore, this study aimed to investigate the biological function of DPY30 in CRC metastasis both in vitro and in vivo. Herein, our results revealed that DPY30 overexpression is significantly positively correlated with positive lymph nodes, epithelial-mesenchymal transition (EMT), and CRC metastasis. Moreover, DPY30 knockdown in HT29 and SW480 cells markedly decreased EMT progression, as well as the migratory and invasive abilities of CRC cells in vitro and lung tumor metastasis in vivo. Mechanistically, DPY30 increased histone H3K4me3 level and promoted EMT and CRC metastasis by upregulating the transcriptional expression of ZEB1. Taken together, our findings indicate that DPY30 may serve as a therapeutic target and prognostic marker for CRC.
DPY30属于组蛋白赖氨酸甲基转移酶复合物组成部分的核心亚基,该复合物与肿瘤发生、细胞衰老及其他生物学事件有关。然而,其对结直肠癌(CRC)进展和转移的作用尚未阐明。因此,本研究旨在探讨DPY30在CRC转移中的体内外生物学功能。在此,我们的结果显示DPY30过表达与阳性淋巴结、上皮-间质转化(EMT)及CRC转移显著正相关。此外,HT29和SW480细胞中DPY30敲低显著降低了EMT进程以及CRC细胞的体外迁移和侵袭能力及体内肺肿瘤转移。机制上,DPY30通过上调ZEB1的转录表达增加组蛋白H3K4me3水平并促进EMT和CRC转移。综上所述,我们的研究结果表明DPY30可能作为CRC的治疗靶点和预后标志物。